GB1002211A - Method of preparing sustained release pharmaceutical tablets - Google Patents
Method of preparing sustained release pharmaceutical tabletsInfo
- Publication number
- GB1002211A GB1002211A GB23432/63A GB2343263A GB1002211A GB 1002211 A GB1002211 A GB 1002211A GB 23432/63 A GB23432/63 A GB 23432/63A GB 2343263 A GB2343263 A GB 2343263A GB 1002211 A GB1002211 A GB 1002211A
- Authority
- GB
- United Kingdom
- Prior art keywords
- water
- solvent
- insoluble
- solution
- lattice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 7
- 239000003814 drug Substances 0.000 abstract 6
- 239000002904 solvent Substances 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000003826 tablet Substances 0.000 abstract 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000000440 bentonite Substances 0.000 abstract 1
- 229910000278 bentonite Inorganic materials 0.000 abstract 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 abstract 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 abstract 1
- 239000008116 calcium stearate Substances 0.000 abstract 1
- 235000013539 calcium stearate Nutrition 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 150000002194 fatty esters Chemical class 0.000 abstract 1
- 239000010685 fatty oil Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002198 insoluble material Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229940068965 polysorbates Drugs 0.000 abstract 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000741 silica gel Substances 0.000 abstract 1
- 229910002027 silica gel Inorganic materials 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000013053 water resistant agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Sustained-release tablets are prepared by dissolving a medicament in a solvent to form a solution, mixing the solution with a water-insoluble lattice-forming material which is insoluble in the solvent, removing said solvent to obtain a substantially dry mixture and compressing said mixture into tablets which thereby have the medicament uniformly dispersed in the lattice structure formed by the water-insoluble material. The lattice-forming material may be aluminium oxide, a water-insoluble metal salt of a fatty acid containing from 6-22 C. atoms e.g. calcium stearate, bentonite, silica gel, barium sulphate, or mixtures thereof. The solvent may be water, a C1-6 alcohol or a mixture thereof. Water-soluble forms of a wide range of drugs may be used e.g. antibiotics, steroids and vitamins. Optional ingredients are (a) inert, water-soluble carriers e.g. urea, glycine, glycol, polyvinyl pyrrolidone, polyvinyl alcohol or mixtures thereof; (b) water-resistant agents e.g. methyl cellulose, fatty acids, fatty alcohols, fatty esters, fatty oils and wax, which slow down the release of the drug; (c) surface-active agents e.g. sodium lauryl sulphate, polysorbates and bis-2-ethylhexyl sodium sulpho-succinate; (d) anti-acid or intestinal fluid solubilising agents e.g. cellulose acetate phthalate, starch acetate phthalate, polyvinyl acetate phthalate or mixtures thereof. The optional ingredients and drug are put into solution and mixed uniformly with the water-insoluble particles. Alternatively, the particles may be sprayed with the said solution of drug and modifiers. In a modification, a non-reactive water-soluble carrier is dissolved in a solvent, the solution is mixed with the water-insoluble lattice-forming material, the solvent is removed, an enzyme is mixed with the dry mixture and the resultant product is compressed into tablets.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201822A US3148124A (en) | 1962-06-12 | 1962-06-12 | Method of preparing sustained release pharmaceutical tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1002211A true GB1002211A (en) | 1965-08-25 |
Family
ID=22747445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB23432/63A Expired GB1002211A (en) | 1962-06-12 | 1963-06-12 | Method of preparing sustained release pharmaceutical tablets |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US3148124A (en) |
| DE (1) | DE1467906A1 (en) |
| GB (1) | GB1002211A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2359607A1 (en) * | 1976-07-27 | 1978-02-24 | Sandoz Sa | NEW PHARMACEUTICAL COMPOSITION ALLOWING A CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE |
| FR2405066A1 (en) * | 1977-05-25 | 1979-05-04 | Commw Scient Ind Res Org | RELEASE COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS TO RUMINANTS |
| US4673527A (en) * | 1985-05-20 | 1987-06-16 | Autotrol Corporation | Tablet granulation |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1467781A1 (en) * | 1963-07-15 | 1968-12-05 | Boehringer Sohn Ingelheim | Process for the production of coated tablets with extended release of active ingredients |
| US3350270A (en) * | 1964-09-18 | 1967-10-31 | Leeds Dixon Lab Inc | Aluminum aspirin film-enveloped therapeutic agents in sustained release dosage form |
| US3400197A (en) * | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| GB1359643A (en) * | 1970-09-28 | 1974-07-10 | Controlled Medications | Controlled release medicament |
| US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
| FR2183546B1 (en) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
| US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
| US3923969A (en) * | 1973-06-12 | 1975-12-02 | Battelle Institut E V | Carrier system for a drug with sustained release |
| US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
| US4291016A (en) * | 1976-07-27 | 1981-09-22 | Sandoz Ltd. | Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate |
| HU174057B (en) * | 1976-09-17 | 1979-10-28 | Richter Gedeon Vegyeszet | Coating material for the regulated release of the active substance in biologically active preparations and process for preparing such preparations with regulated release of the active substance |
| DE2845326C2 (en) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Use of a specific microdisperse, amorphous, porous silica for the production of digoxin-containing tablets with a strongly accelerated release of active ingredient |
| FI63335B (en) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | FARING REFERENCE FOR A TABLETTER WITH A LIGHT LIGHT OF AN EFFECTIVE |
| JPS55153715A (en) * | 1979-05-18 | 1980-11-29 | Nikken Kagaku Kk | Prolonged granule of theophylline |
| US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4547358A (en) * | 1980-05-06 | 1985-10-15 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| JPS6056122B2 (en) * | 1980-05-21 | 1985-12-09 | 塩野義製薬株式会社 | sustained release formulation |
| US4465660A (en) * | 1981-04-01 | 1984-08-14 | Mead Johnson & Company | Sustained release tablet containing at least 95 percent theophylline |
| GB2186485B (en) * | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
| DE3827214A1 (en) * | 1988-08-11 | 1990-02-15 | Roehm Gmbh | RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF |
| WO2001012221A1 (en) * | 1999-08-16 | 2001-02-22 | Henceforth Hibernia, Inc. | Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
| TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
| EP1663156A2 (en) * | 2003-09-19 | 2006-06-07 | Penwest Pharmaceuticals Company | Chronotherapeutic dosage forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2918411A (en) * | 1957-11-01 | 1959-12-22 | Olin Mathieson | Pharmaceutical preparations |
| US2957804A (en) * | 1958-06-06 | 1960-10-25 | Harlan R Shuyler | Pesticide |
| US3102845A (en) * | 1960-11-18 | 1963-09-03 | Mcneilab Inc | Pharmaceutical tablet |
-
1962
- 1962-06-12 US US201822A patent/US3148124A/en not_active Expired - Lifetime
-
1963
- 1963-06-12 DE DE19631467906 patent/DE1467906A1/en active Pending
- 1963-06-12 GB GB23432/63A patent/GB1002211A/en not_active Expired
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2359607A1 (en) * | 1976-07-27 | 1978-02-24 | Sandoz Sa | NEW PHARMACEUTICAL COMPOSITION ALLOWING A CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE |
| FR2405066A1 (en) * | 1977-05-25 | 1979-05-04 | Commw Scient Ind Res Org | RELEASE COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS TO RUMINANTS |
| US4673527A (en) * | 1985-05-20 | 1987-06-16 | Autotrol Corporation | Tablet granulation |
Also Published As
| Publication number | Publication date |
|---|---|
| US3148124A (en) | 1964-09-08 |
| DE1467906A1 (en) | 1969-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1002211A (en) | Method of preparing sustained release pharmaceutical tablets | |
| SU1743332A3 (en) | Process for producing tablets | |
| US4540685A (en) | Process for the production of readily soluble 5-aminosalicylic acid preparations, compositions and methods of use | |
| ATE127686T1 (en) | PRODUCTION PROCESS OF MICRO SPHERE. | |
| ES8502333A1 (en) | A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET | |
| HU175875B (en) | Process for producing 4-bracket-monoalkyl-amino-bracket closed-benzoic acids, esters and pharmaceutically acceptable salts thereof, and pharmaceutical compositions of hypolipidemic activity containing them as active agents | |
| GB1405088A (en) | Slow release formulation | |
| US3361632A (en) | Medicinal preparations having a protracted activity and method of making them | |
| GB1296505A (en) | ||
| US3039933A (en) | Ethyl cellulose-polyethylene glycol tablet matrix | |
| GB953626A (en) | Enteric-coated tablets of dextran sulphate ester and method of preparation thereof | |
| DE69011836D1 (en) | Process for the manufacture of tablets containing spray-dried naproxen or naproxen sodium salt. | |
| IL46539A0 (en) | Esters of dihydroapovincaminic acid,their preparation and pharmaceutical compositions containing them | |
| GB630439A (en) | Improvements in or relating to pharmaceutical preparations | |
| ES297425A1 (en) | Procedure for preparing pharmaceutical compositions in the form of deferred action tablets (Machine-translation by Google Translate, not legally binding) | |
| EG11811A (en) | Process for preparing of anthelmintically active 2-carbalkoxyamino benzimidazolyl-5(6)sulfonic acid phenyl esters and their use for combatting diseases coused by parasites in human and animals | |
| US2553806A (en) | Enteric composition and method of making same | |
| GB908282A (en) | Coated pharmaceutical granules and tablets thereof | |
| CZ382696A3 (en) | Medicinal form containing carbamazepine with delayed release of active component | |
| IL34950A0 (en) | Esters of thiazolo-phosphoric and-phosphonic,thiazolothionophosphoric and thionophosphonic acids,their preparation and use as insecticides and acaricides | |
| NL166277C (en) | PROCESS FOR PREPARING MIXED ESTERS OF HYDROXYCARBONIC ACIDS AND PARTIAL FATTY ACID GLYCERIDES. | |
| JPH0420889B2 (en) | ||
| JPS5484020A (en) | Composition for coating medicine and method for coating the same | |
| JPS5616409A (en) | Gamma-oryzanol pharmaceutical preparation | |
| JPS5892615A (en) | Preparation of long-acting cephalexin preparation |